Trial of Psilocybin versus Escitalopram for Depression
Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind,
Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind,
Importance Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or
Background Psilocybin is being studied for use in treatment-resistant depression. Methods In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression
Background and Aims Very few studies have reported the effectiveness of ibogaine as a treatment for chronic opioid use. Therefore, this study evaluated the acute
Background Natural speech analytics has seen some improvements over recent years, and this has opened a window for objective and quantitative diagnosis in psychiatry. Here,
Introduction It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In
Background Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about
Rationale Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations.
©2025 Unlimited Sciences. All rights reserved.
We hate pop-ups as much as you do, but if you want to stay up to date about the latest news in the psychedelic space and learn about our ground-breaking psychedelic research, please consider signing up for our newsletter below.